ZONEGRAN. NEW IN EVIDENTIAL PHARMACOTHERAPY OF EPILEPSY: OPPORTUNITIES AND EXPECTATIONS
Abstract: this article represents review of literature devoted to a new antiepileptic drug Zonegran (zonisamide, ZNS). History of successful clinical use of ZNS in world practice lasts for 25 years. Zonisamide is on the Russian market from 2014 and is approved for monotherapy and adjunctive therapy...
Main Author: | I. G. Rudakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2016-05-01
|
Series: | Эпилепсия и пароксизмальные состояния |
Subjects: | |
Online Access: | https://www.epilepsia.su/jour/article/view/33 |
Similar Items
-
Safety and Efficacy of Zonisamide in Refractory Epilepsy Patients: Clinical Experience from a Tertiary Center
by: Songül ŞENADIM, et al.
Published: (2018-04-01) -
NEW OPPORTUNITIES PHARMACOTHERAPY PATIENTS WITH REFRACTORY EPILEPSY
by: P. N. Vlasov
Published: (2017-03-01) -
Immune‐mediated polyarthritis and anterior uveitis secondary to zonisamide administration in a dog with refractory epilepsy
by: Paula Baya, et al.
Published: (2024-03-01) -
Upregulated Connexin 43 Induced by Loss-of-Functional S284L-Mutant α4 Subunit of Nicotinic ACh Receptor Contributes to Pathomechanisms of Autosomal Dominant Sleep-Related Hypermotor Epilepsy
by: Kouji Fukuyama, et al.
Published: (2020-03-01) -
Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan
by: Shino Yoshida, et al.
Published: (2023-07-01)